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Abstract  
Combinatorial therapeutic approaches are an imperative to improve cancer 
treatment, since it is critical to impede compensatory signaling mechanisms that 
can engender drug resistance to individual targeted drugs. Currently approved 
drug combinations result largely from empirical clinical experience and cover 
only a small fraction of a vast therapeutic space. Here we present a 
computational network biology approach, based on pathway crosstalk 
inhibition, to discover new synergistic drug combinations for breast cancer 
treatment. In silico analysis identified 390 novel anti-cancer drug pairs 
belonging to 10 drug classes that are likely to diminish pathway crosstalk and 
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display synergistic anti-tumor effects. Ten novel drug combinations were 
validated experimentally, and seven of these exhibited synergy in human breast 
cancer cell lines. In particular, we found that one novel combination, pairing the 
estrogen response modifier raloxifene with the c-Met/VEGFR2 kinase inhibitor 
cabozantinib, dramatically potentiated the drugs’ individual anti-tumor effects 
in a mouse model of breast cancer.  When compared to high-throughput 
combinatorial studies without computational prioritization, our approach offers 
a significant advance capable of uncovering broad-spectrum utility across many 
cancer types. 
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Introduction 
Breast cancer is a very heterogeneous disease regarding the underlying 
molecular alterations, the cellular composition of tumors, and the different 
clinical outcomes (1), which hampers the design of effective treatment strategies 
(2). To account for this intrinsic diversity, drug discovery efforts have shifted 
towards mechanism-based and target-oriented strategies, particularly aiming at 
modulating specific molecular pathways, patient-specific genetic alterations and 
the tumor microenvironment (3,4).  
Despite the expanding repertoire of new anti-cancer agents, treatment failure 
remains a major challenge in the management of most advanced solid cancers, 
including breast cancer (5,6). Multiple compensatory mechanisms are known to 
counterbalance therapeutic effects, eventually leading to treatment failure (6). 
One of the most promising strategies for better clinical outcomes is the use of 
combinatorial therapy to target the distinct adaptive response mechanisms (7,8), 
which may also help to overcome toxicity associated with higher doses of single 
drugs. In addition, synergistic drug combinations are often more specific and 
therefore improve the therapeutically relevant selectivity (9). However, although 
becoming the standard care in (breast) cancer treatment, most approved drug 
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combinations are the result of empirical clinical experience, and often rely on 
similar mechanisms of action as pre-existing drug combinations, which 
prevented a systematic sampling of the therapeutic space (Supplemental Fig. 
S1). 
Identifying drug combinations with therapeutic effect remains a challenging task 
given the exhaustive number of possibilities. Different approaches are available 
for predicting drug combinations for complex diseases, mostly including 
mathematical modeling, stochastic search techniques, as well as cell context-
based methods like global gene expression or targeted phospho-proteomics 
profiling (10-13). More recently, network-based models have been proposed for 
identifying drug synergies and for examining the mechanisms of action of 
efficient combinations (14-16). 
Experimental studies have shown that cancer cells are able to adapt signaling 
pathway circuits upon drug treatment by establishing alternative signaling 
routes through crosstalk (17,18). Hence, a critical aspect to improve cancer 
treatment is not only to inhibit the primary oncogenic pathways that induce 
abnormal cell proliferation but, simultaneously, to prevent functional 
redundancies and pathway crosstalk that facilitate survival of cancer cell 
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populations rendering tumors resistant to therapy. Current network 
pharmacology principles aim for a synergistic multi-target intervention strategy 
to improve clinical efficacies, while tackling critical aspects such as drug 
resistance (19,20). In line with this idea, we have derived a network-based 
computational method to quantify the crosstalk between signaling pathways 
involved in breast cancer and we assessed how combinatorial perturbations 
impact the signaling crosstalk. We then applied this measure to a set of 
approved and experimental breast cancer drugs to identify combinations, which 
could efficiently diminish pathway crosstalk and thereby increase clinical 
efficacy. Finally, we experimentally validated novel drug combinations in several 
human breast cancer cell lines and confirmed the in vivo synergistic effect 
between two drugs in mouse xenografts, emphasizing the potential clinical 
relevance of our strategy. 
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Material and Methods 
Breast cancer drugs 
We compiled a comprehensive set of drugs that are either prescribed or in 
clinical trials for breast cancer treatment. Primary information on FDA-approved 
breast cancer drugs has been gathered from the National Cancer Institute (NCI). 
This data has been complemented with information from DrugBank 3.0 (21) and 
the therapeutic targets database TTD (22). Overall, we collected 64 breast cancer 
agents of which 32 are approved. The number of experimental compounds used 
for breast cancer treatment is most likely higher; yet, the data is scattered across 
the literature, not accessible in an automatic manner and often there is no 
available information on the modulated therapeutic target(s). 
Each drug has been associated with its therapeutic target(s). For drugs from 
DrugBank, we considered only primary targets. Only if none of the targets have 
a known pharmacological action we consider all targets for that drug. Targets 
from TTD were treated as primary therapeutic targets. We further extracted 
pathways and biological processes that are most likely modulated by a drug 
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through its target(s). Pathway information was retrieved from the KEGG 
database (23). 
Depending on the mechanism of action, we divided drugs into cytotoxic and 
targeted agents. Furthermore, we classified the set of breast cancer drugs 
according to their therapeutic target(s) into 11 drug classes. The complete set of 
breast cancer drugs considered can be found in Supplemental Table S1. 
Breast cancer drug combinations of clinical relevance 
We extracted drug combinations considered for breast cancer therapy by 
mining the Drug combination database (DCDB) (24), the FDA orange book (25), 
the NCI and the ClinicalTrials.gov (26). In total, 170 drug combinations were 
obtained. Some of them are already approved while the majority is currently in 
clinical trials. Supplemental Fig. S1 provides an overview of the current drug 
combinations with respect to the 11 drug classes. 
Therapeutic signaling networks and pathway crosstalk inhibition 
To chart the therapeutic networks associated with each drug, we compiled all 
those KEGG pathways (excluding disease pathways) that include any of the 
primary targets of the drug. On average each drug affects 6.5 KEGG pathways 
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(median = 3, sd ± 8.3). Given the XML representation of a pathway, we created a 
directed network including proteins and their interactions whereas the type of 
an interaction, such as activation or inhibition, was used to determine the 
directionality of an edge in the network.  
Based on the therapeutic signaling networks, we developed a crosstalk 
inhibition measure to estimate the amount of crosstalk signaling that can be 
prevented between pathways by inhibiting specific proteins simultaneously. The 
concept of pathway crosstalk refers to protein interactions shared between 
distinct pathways. Since these interactions might also influence the downstream 
signaling within a pathway, the concept also comprises proteins and interactions 
downstream of the respective crosstalking interactions (i.e. indirect crosstalk; 
Fig. 1).  
Given two therapeutic signaling networks, we determined the potential crosstalk 
between them by identifying interactions directly and indirectly involved in the 
crosstalk, and representing them as a directed crosstalk network. Using this 
crosstalk representation, we then applied a topology-based measure, namely 
network efficiency (27), to determine the information flow within the network. 
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Network efficiency (NE) is defined as the sum of the inverse length of the 
shortest path between all network elements and can be computed as follows: 
ܰܧ =  
∑ 1݀(݅, ݆)௜ஷ௝
ܰ(ܰ − 1) , 
with N representing the number of network elements and d denoting the 
shortest distance between two elements i, j Є N. The network efficiency ranges 
between 0 and 1, where 1 indicates that all proteins communicate directly with 
each other, i.e., a fully connected network. 
Using the network efficiency determined for crosstalking pathways, as described 
above, we simulated the inhibition of specific protein target(s) and measured 
the amount of signaling that persists (NEX) when removing protein interactions 
affected by a pharmacological intervention. We determined the relative 
reduction of network efficiency, i.e., the pathway crosstalk inhibition (PCI), as 
follows: 
ܲܥܫ = 1 − ܰܧ௑ܰܧ . 
The final PCI for a given pair of breast cancer drugs is the average of the 
crosstalk inhibitions between each pair of crosstalking pathways forming the 
respective therapeutic networks.  
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Experimental validation of drug combinations 
Drug combination experiments were conducted in five cell lines, four of them, 
namely MCF-7, MDA-MB-231, SKBR3 and BT474, representing distinct breast 
cancer subtypes. In addition, we also included U2OS, a bone osteosarcoma cell 
line, representing a widely used cancer cell line. When analyzing a combination, 
we tested the activity of the individual drugs D1 and D2, and the combination at 
four concentrations, selected from the literature to cover their activity range 
(Supplemental Table S2). To assess the cytostatic/cytotoxic effects of a single 
drug or a drug combination in cell lines, we employed the MTT assay for 
measuring cell viability (28).  
Cells were seeded at 1,000 to 5,000 cells per well in 96-well flat-bottom cell 
culture plates. After 24 h of incubation at 37ºC with 5% CO2, cells were exposed 
to four concentrations of drug or drug combinations for 72 or 120 h 
(Supplemental Table S2). Cell survival was determined using an MTT-based 
assay. All experiments were either performed in triplicates (individual drugs) or 
quadruplicates (drug combinations); repeated three independent times. 
Further details on cell lines, culture conditions and drugs can be found in the 
Supplemental Information (Supplemental Section S1). 
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Drug combination index 
Given the MTT cell viability measurements, we assessed whether a drug 
combination induces additive, synergistic or antagonistic effects in cultured 
cells. To this end, we determined the drug combination index (DCI) using the 
Loewe additivity as a reference model, assuming that a drug cannot interact 
with itself (29,30). This means that if two drugs are the same or very similar, we 
expect their combined effect at equal concentrations to be comparable to the 
one observed when administering one drug alone at double concentration. 
The DCI of a combination is computed based on the half-maximal effective 
concentration that is needed to inhibit cell viability by X%, with X commonly 
corresponding to an inhibition level of 50% (i.e. IC50). Formally, the DCIX is 
defined as follows: 
DCIX= 
Cୈଵ,ଡ଼
ICX,D1
+ Cୈଶ,ଡ଼ICX,D2
 
CD1,X and CD2,X represent the concentration of drug D1 and drug D2 used in 
combination to induce an effect X while ICX,D1 and ICX,D2 indicate the 
corresponding concentrations of the single agents required to produce the 
same effect. In other words, the DCI measures the fractional shift between single 
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and combinatorial concentrations yielding an inhibition of cell survival of X%. 
The concept of the DCI is exemplified for one combination in Supplemental Fig. 
S2. Using this measure, we can quantify synergistic, additive and antagonistic 
combinatorial effects, commonly defined as DCI < 0.85, DCI ~1 and DCI > 1.2, 
respectively (Supplemental Table S3). 
ICX values can be determined from dose-response curves for any inhibition level 
X. Here, we used the drc R package to generate sigmoid-fitted dose-response 
curves from which we then estimated the ICX for single drugs and combinations 
(31). In some cases the single agents do not reach the pre-defined inhibition 
level while in others the estimated ICX corresponds to a value beyond the tested 
concentration range. In the latter one, we exploited the relative standard error 
(RSE) associated with each fit to decide whether to consider an ICX (16). The 
influence of using different RSE thresholds for determining the DCI is discussed 
in Supplemental Section S2 and Table S4. No DCI is reported for cases where 
neither the single nor the combined inhibition induces the desired effect. 
Dose reduction index 
A major aim of synergistic drug combinations is to reduce the dose of a drug, 
thereby reducing toxicity while maintaining therapeutic efficacy. The dose 
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reduction index (DRI) measures to which extent the concentration of a drug in 
combination can be reduced at a given inhibition level X compared with the 
concentration of an individual drug alone. 
DRIX,Dభ= 
ICX,D1
େీభ,౔,  DRIX,Dమ= 
ICX,Dమ
େీమ,౔ 
In general, a DRI above 1 is considered to be beneficial. Furthermore, larger DRIs 
correlate with a larger magnitude of dose reduction for a given therapeutic 
effect.  
Mouse xenograft model 
MCF-7 human breast cancer cells were prepared in a 1:1 PBS:Matrigel (BD 
Biosciences) mixture and 1x106 cells were injected directly into the mammary 
gland. When tumors reached a volume of 120-150 mm3, mice were randomly 
assigned to different groups and treated for 15 days with cabozantinib (oral 
gavage, 2 mg/kg), raloxifene (i.p. 6 mg/kg), the combination of both (1 mg/kg of 
cabozantinib and 3 mg/kg of raloxifene), or the corresponding vehicles. At day 
15, mice were sacrificed and tumors were formalin-fixed and paraffin-
embedded. Sections were stained with haematoxylin and eosin (H&E), Ki67 
(Novocastra) and the “In situ cell Death Detection Kit, Fluorescein” (Roche), 
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following manufacture’s instructions. Western blot analysis was used to 
measure the activity of selected proteins in tumor samples of the different 
groups. Further details can be found in the Supplemental Information (Section 
S3). For determining the statistical difference between the treatment groups we 
used the one-sided t-test. 
 
Results 
Pathway crosstalk inhibition (PCI) as a tool for inferring synergistic drug 
combinations 
Alternative signaling through pathway crosstalk is one of the main mechanisms 
leading to treatment failure (18). Therefore, we devised a computational 
strategy to infer drug combinations that specifically addresses this problem. Our 
approach is based on the quantification of the level of crosstalk between 
signaling pathways that can be prevented by simultaneously inhibiting specific 
sets of proteins. The concept of pathway crosstalk refers to shared protein 
interactions between distinct signaling cascades, and the interactions 
downstream of the ones that crosstalk (Fig. 1). To determine pathway crosstalk 
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and inhibition, we first built the therapeutic networks associated with each 
individual drug by considering its set of known primary targets mapped onto 
well-annotated canonical pathways (23). We found that, on average, each drug 
can be associated with 6.5 signaling pathways, the sum of which constitutes its 
therapeutic signaling network. Interactions directly or indirectly (i.e. 
downstream) involved in crosstalk between drug pathways were integrated into 
a signaling network in which we then assessed the levels of crosstalk inhibition 
through individual or combinatorial target perturbations. Using a topology-
based measure of network efficiency (27), we computed the flow of information 
within a crosstalk network before and after inhibiting individual or combined 
drug targets. Drug combinations with a high impact on PCI are expected to 
present promising drug combinations. 
To examine the clinical relevance of the PCI for inferring novel drug 
combinations, we assessed its applicability on approved or tested breast cancer 
drug combinations. To this end, we generated all pairwise combinations from 
the 64 available breast cancer agents (Supplemental Table S1) examining which 
of them are currently used for therapy or in clinical trials. Of the potential 2,016 
combinations, 170 are documented as tested by the ClinicalTrial.gov (26), the 
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FDA orange book, the NCI 
(http://www.cancer.gov/cancertopics/druginfo/breastcancer) or the DCDB (24). 
We considered these as clinically relevant combinations for breast cancer. The 
remaining ones constituted a set of non-tested combinations. Given the two 
sets, we computed the pathway crosstalk inhibition among the combined drugs. 
Since pathway crosstalk, as defined here, may only occur among related 
pathways sharing components, we only considered drug pairs whose pathways 
have at least a common protein, yielding a total of 1,132 combinations, 86 of 
which are among the 170 considered clinically relevant. 
In general, we find that pathway pairs involved in clinically relevant 
combinations share a significantly higher portion of proteins and exhibit a 
higher crosstalk compared to a background of all human KEGG pathways (p-
value < 2.2e-16; Supplemental Section S4 and Fig. S3).  When specifically 
assessing the potential pathway crosstalk inhibition achieved by drug 
combinations, we observed that those in clinical use have a significantly higher 
impact on PCI than randomly combined pairs of drugs (Fig. 2A), with an average 
PCI of 0.34 compared to 0.25 (p-value = 8.96·10-6). Indeed, for the few clinical 
drug combinations where efficacy data are available, we found that those 
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exceeding the average PCI of 0.34 are more likely to show clinical efficacy (p-
value = 0.03215; Supplemental Section S5 and Fig. 2A and S4). This implies that 
crosstalk inhibition may be, one of the molecular mechanisms exploited by a 
number of successful breast cancer drug combinations.  
In addition, we assessed the PCI for 68 synergistic, additive or antagonistic drug 
pairs identified in a combination screen performed in a tumor-derived 
liposarcoma cell line (DDLS817) considering 14 targeted compounds from 
distinct drug classes (16). This screen resulted in 14.3% synergistic, 38.5% 
additive and 22% antagonistic combinations. Figure 2B demonstrates that 
synergistic combinations have a significantly higher PCI than non-synergistic 
drug pairs and particularly antagonistic ones, with average values of 0.35 
compared to 0.22 (p-value = 0.00341) and 0.18 (p-value = 0.00069), respectively. 
A significant correlation between PCI and drug combination index can be also 
observed as shown in Figure S5 (Pearson correlation coefficient = -0.439, p-
value = 0.0001829). Furthermore, the average PCI of synergistic combinations is 
comparable to the one determined for clinically relevant combinations. 
Overall, the two complementary evaluations support the value of our approach 
to identify effective drug combinations. 
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Identification of novel drug combinations 
Among the randomly combined drugs, we found a large number of 
combinations showing a high impact on the crosstalk inhibition between breast 
cancer pathways (Fig. 2A and Supplemental Table S5). These drug pairs are 
promising candidates for combinatorial treatment since the pathway crosstalk 
identified is directly involved in breast cancer-related processes. To select the 
most relevant ones, we used as a threshold the mean PCI of 0.34 observed in 
the drug combination sets that are clinically used. This includes 62.8% of the 
clinically relevant combinations, exhibiting a higher likelihood of possessing 
clinical efficacy (Supplemental Fig. S4), but only 37.3% of the random set of 
combinations (Supplemental Fig. S6). Overall, 390 novel drug combinations 
showed a PCI ≥ 0.34, including drugs from 10 different classes, which are 
therefore likely to exhibit synergistic effects. Furthermore, pathway pairs 
affected by the novel drug combinations showed a significantly higher protein 
overlap as well as a higher pathway crosstalk compared to all human KEGG 
pathways with a p-value < 2.2e-16 (Supplemental Section S4 and Fig. S3). Not 
surprisingly, the majority of these combinations (370) occur between drugs 
belonging to different therapeutic subclasses, showing the ability of our method 
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to prevent redundant mechanisms of action. Moreover, about 65% of the new 
combinations include therapeutic classes never tested together before, 
expanding the sampling of the potential therapeutic space. We believe that 
these drug pairs have the potential to increase treatment efficacy by inhibiting 
oncogenic pathways at distinct points, as well as by reducing the concentration 
needed for inducing a given effect, which consequently improves their 
therapeutic index. A full description of the suggested drug combinations, 
together with the therapeutic pathways involved in the crosstalk inhibition, is 
provided in Supplemental Table S5. 
Experimental validation of selected drug combinations 
The fundamental aim of any combinatorial strategy is its therapeutic application. 
Therefore, we selected a subset of drug combinations to experimentally assess 
their effects on the proliferation of tumor cells, a key process for tumorigenesis. 
During the selection process, we only considered truly novel drug combinations; 
hence omitting those which resemble approved or tested ones (Supplemental 
Fig. S1). Trastuzumab, for instance, is administered in combination with 
paclitaxel and tamoxifen (32,33), thus we disregarded combinations including 
HER2 inhibitors together with microtubule or estrogen receptor modulators. We 
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selected ten combinations from the remaining pool according to their overall 
potential for crosstalk inhibition, involving ten targeted drugs and one cytotoxic 
agent (Fig. 3 and Table 1). To maximize the sampling of the combinatorial 
therapeutic space, we only selected the highest PCI per representative drug 
class combination. 
We then studied the effect of the selected drug combinations in five human 
cancer cell lines, four of them representing distinct breast cancer subtypes (Fig. 
4A), namely triple-negative (MDA-MB-231), hormone receptor-positive (MCF-7), 
HER2-overexpressing (SKBR3) and triple-positive (BT-474) breast cancer, while 
the fifth was derived from osteosarcoma (U2OS). For the quantification of 
cytotoxic effects induced by individual drugs or drug combinations, we used the 
MTT assay, which measures cell proliferation and viability (28) (Supplemental 
Section S1). 
To determine if the tested combinations were of synergistic, additive or 
antagonistic nature, we computed the Loewe additivity-based drug combination 
index (DCIX) for each combination in each cell line (30). The DCIX compares the 
half-maximal effective concentrations for inhibiting X% of cell viability of single 
agents with the concentration derived for a combination. To avoid 
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overestimating the number of synergistic combinations and, to some extend, 
account for cell line variability, we adopted a more stringent definition of 
synergy (Supplemental Table S3), considering a DCIX below 0.85 as synergistic. A 
DCIX above 1.2 indicates antagonism while any value in-between depicts 
additivity (0.85 > DCIX ≤ 1.2) (29). 
Considering an inhibition level of 50%, we generated sigmoid-fitted dose-
response curves based on the MTT assays from which we then estimated IC50 
and DCI50 values (Supplemental Fig. S2 for an example and S7 for all dose-
response curves). Figure 4B shows the DCI50 derived for each combination in the 
five cell lines. Our results showed that seven out of ten combinations tested 
displayed a synergistic behavior in, at least, one cancer cell line. Overall, we 
found that 32% of the combinations were synergistic, 38% were additive, and 
16% exhibited antagonistic effects in human cancer cell lines. For another 14% 
we could not determine a reliable DCI. Interestingly, the fraction of synergistic 
drug combinations slightly increased up to 35% when analyzing only breast 
cancer cell lines. These numbers emphasize the significant enrichment of 
synergistic drug combinations compared to traditional experimental high-
throughput screens (p-value < 1e-04, Supplemental Fig. S8A and S8B), which 
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detect synergy in 4 to 14% of the drug pairs tested (16,34,35). A detailed 
description of the comparison can be found in the Supplementary Material 
(Section S6).  
 The per-combination perspective shows that the selected combinations are 
synergistic in a broader extent than anticipated a priori (Supplemental Fig. S9), 
given the heterogeneity of breast cancer (36,37). For instance, DC07 is 
synergistic in four cancer cell lines, DC04 and DC09 in three, DC02 and DC10 in 
two, and DC05 and DC06 in one. 
When analyzing drug combinations separately, we observed clear correlations 
between the degree of synergy and the molecular features of each cancer cell 
line. In the case of DC09, trastuzumab combined with cabozantinib, a very 
strong synergy was identified in the HER2-overexpressing SKBR3 cells. Strong 
synergy was also observed for triple-positive cancer cells (BT-474), which 
express in addition to HER2, the estrogen and progesterone hormone receptors. 
Yet, in MCF-7 cells that lack HER2 overexpression, DC09 still showed some 
synergy, although decreased. In turn, complete lack of HER2 in the triple-
negative and osteosarcoma cells revealed antagonistic interactions between 
trastuzumab and cabozantinib. The opposite trend was visible for DC10, 
 24
raloxifene and NVP-AEW541, which showed the best synergy in MCF-7 cells 
followed by BT-474 cells, while an additive effect was detected for SKBR3 cells. 
Surprisingly, a strong synergy was obtained for DC04 in MCF-7 cells and SKBR3 
cells, although this combination includes a PARP1 inhibitor, which is expected to 
be effective in triple negative breast cancers (38). Note that, although individual 
breast cancer drug indications might give insights on the synergistic 
mechanisms of a combination in a certain cancer subtype (Supplemental Table 
S6), experiments in a larger cell panels would be required to elucidate the 
mechanism of synergy of a combinations regarding a certain cancer subtype.  
When considering the combinatorial effects with respect to the individual cancer 
cell lines, we observed that MCF-7 cells and SKBR3 cells tend to be more 
sensitive towards the selected drug combinations, with 50% being synergistic 
and the remaining ones showing at least additive effects (Supplemental Fig. 
S10). Again, this enrichment is significant with respect to high-throughput 
screens (p-value = 5e-04, Supplemental Fig. S8C). In turn, 30% of the 
combinations were antagonistic in U2OS cells and BT-474 cells, and 20% were 
antagonistic in MDA-MB-231 cells. These observations might reflect the 
prevalence of therapeutic strategies, i.e., drugs and combinations, for the more 
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common hormone receptor-positive and HER2-overexpressing breast cancer 
subtypes. 
U2OS cells were included as additional cancer cell line to examine the specificity 
of synergistic effects, since we recently found that individual anti-cancer drugs 
designed for a particular cancer (sub)type do not show a significantly higher 
activity in cancer cell lines derived from that specific tumor type (39).  
Although the IC50 is the most used index to measure the effectiveness of a 
compound at inhibiting a specific biological function, we examined the potential 
effect of concentration-dependent pharmacodynamic interactions, we 
determined the DCI for a series of inhibition levels ranging from 20% to 80%, 
which corresponds to DCI20 to DCI80. Overall, we found our results to be fairly 
robust, with 68.3% of the combinations showing a consistent interaction 
behavior, independently of the inhibition level considered - i.e. we found neither 
synergistic-antagonistic nor additive-antagonistic shifts (Supplemental Fig. 
S11A). 
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Effect of the raloxifene and cabozantinib combination in a xenograft 
mouse model 
The experimental validation in cancer cell lines revealed a clear synergistic 
therapeutic effect for combination DC02 (raloxifene with cabozantinib) in 
hormone receptor-positive breast cancer cells (DCI50 = 0.39). Our computational 
model suggested that the observed crosstalk inhibition was the result of the 
simultaneous modulation of estrogen signaling together with the PI3K/AKT and 
VEGF pathways by the two drugs, which should not only reduce the growth of 
the primary tumor but also its ability to spread. Interestingly, we found that this 
particular combination exhibited a dose reduction index of 51.9 and 2.66 for 
raloxifene and cabozantinib, respectively. In other words, to achieve the same 
inhibition level, the doses of the individual drugs could be significantly reduced 
when combined (Fig. 5). Finally, its DCI showed a remarkably consistent 
synergistic behavior in MCF-7 cells throughout all the inhibition levels 
(Supplemental Fig. S11B). 
We thus examined the impact of DC02 in vivo, using MCF-7 cells orthotopically 
implanted in nude mice, which were treated for 15 days with cabozantinib, 
raloxifene or the combination of both. We selected concentrations of 1 mg/kg 
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for cabozantinib and 3 mg/kg for raloxifene (low doses) that were previously 
reported to have a minor or no effect on tumor growth in related conditions 
(40,41). However, since mice treated with the combination were exposed to 
higher overall drug doses, we assessed the effect of the individual drugs on 
tumor growth doubling their concentrations. Thus, we applied 2 mg/kg for 
cabozantinib and 6 mg/kg for raloxifene to avoid that a stronger effect observed 
for the combination is merely induced by the higher drug concentration 
administered in the combinatorial treatment. 
We found that treating tumor-bearing mice with cabozantinib or raloxifene 
alone induced a cytostatic effect on tumor growth (Fig. 6A). Strikingly, in 
agreement with our observations in cultured cell lines and the crosstalk 
inhibition model, the combined treatment of mice with lower doses of 
cabozantinib and raloxifene showed a clear synergistic effect reducing the size 
of the tumors by more than 60% (Fig. 6A). Despite its dramatic impact on tumor 
growth, the combination has no effect on the body weight and none of the 
animals demonstrated abnormalities in their behavior, indicating that the 
combinatorial treatment is not more stressful than individual treatments 
(Supplemental Fig. S12). To explore whether the molecular processes leading to 
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tumor reduction were indeed the ones suggested by the crosstalk inhibition 
model, we performed immunohistochemical analyses of tumor sections at the 
end of the treatment (day 15). TUNEL staining assays showed slightly increased 
cell death levels in tumors from cabozantinib-treated mice but no differences in 
the raloxifene-treated mice, which is consistent with observations in ER+ human 
breast tumors (42). Interestingly, when combining both drugs, cell death levels 
increased 9.5 times compared with the initial or vehicle-treated tumors (Fig. 6B 
and 6C). We also found that cell proliferation, based on Ki67 staining, was 
strongly inhibited in tumors from mice treated with raloxifene and, to an even 
larger extent, in tumors from mice treated with the combined drugs (Fig. 6D). 
We did not observe any effect on cell proliferation in tumors from cabozantinib-
treated mice.  
The effects on cell proliferation and cell death, as detected in the xenograft 
mouse tumors, were in line with the current knowledge on the mechanism of 
action of both drugs (40,42-44). To further assess pathway crosstalk inhibition 
for DC02 at the molecular level, we performed western blotting with tumor 
samples. In particular, we analyzed the activity of proteins involved in the 
pathways that were predicted to be modulated predominantly by the drug 
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combination, including Akt and Src and the nuclear form of the estrogen 
receptor (nER) (Fig. 6E). We found that the drug combination had a stronger 
effect than the individual drugs on the activities of both Src and Akt, which was 
also clear analyzing downstream members of the pathways such as Bcl2 and 
cyclin D1 (Fig. 6F). These results are consistent with the proposed effect of the 
drug combination on crosstalk signaling and the reduced tumor growth 
observed in the xenografts. 
Taken together, our study confirms that the combination of cabozantinib and 
raloxifene has a stronger therapeutic effect in vivo than the single drugs at 
higher doses. Our results indicate that the dramatic, synergistic effect of the 
combination on tumor growth emerges from the simultaneous induction of cell 
death by cabozantinib and the inhibition of cell proliferation by raloxifene. 
These mechanistic insights agree with the crosstalk inhibition calculated for 
DC02, which mostly comes from the simultaneous modulation of estrogen and 
prolactin signaling together with the PI3K/AKT and VEGF signaling pathways by 
the two drugs. Thus, as suggested by our model, inhibiting the crosstalk 
between these pathways prevents alternative signaling events, which regulate 
cell proliferation and survival. 
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Discussion 
Combinatorial therapy is a very promising strategy for improving cancer 
treatment. The combination of drugs allow to interfere with compensatory 
mechanisms, often related to treatment failure, using drug concentrations that 
are less toxic than the high doses of single drugs usually required to achieve 
similar effects. However, despite its great potential, most approved drug 
combinations are the result of empirical clinical experience and, not being 
rationally designed, cover only a small fraction of the vast therapeutic space. In 
this study, we have presented a computational network biology approach to 
identify potentially synergistic drug combinations against breast cancer. Even 
though we focus specifically on pathway crosstalk as a major contributor to 
treatment failure, other oncogenic features, such as gene mutations, might also 
be helpful for finding combinatorial treatment (45). Overall, our strategy has 
identified a set of anti-cancer drug pairs with a large impact on crosstalk 
inhibition. The experimental validation of ten selected novel combinations 
confirmed a synergistic behavior for seven of them in, at least, one of the four 
breast cancer cell lines tested. This represents a significant enrichment 
compared to combinatorial studies without computational prioritization. 
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Furthermore, we confirmed that raloxifene combined with cabozantinib has a 
dramatic synergistic effect interfering with tumor growth in vivo using a mouse 
xenograft model based on MCF-7 human breast cancer cells, supporting the 
potential clinical relevance of our strategy. Even though further research is 
required to enable the translation of a promising combination into therapeutic 
strategies, our results show that approaches focusing on the inhibition of 
crosstalk between pathways could provide valuable mechanistic information to 
discover synergistic drug effects. Moreover, we centered our study on breast 
cancer, but we believe that our approach can be also applied to other complex 
diseases, in which pathway crosstalk is likely to play an important role. 
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Tables 
Table 1:  List of drug combinations selected for experimental validation. For each 
combination, we specified the respective drug classes as well as the overall pathway 
crosstalk inhibition (PCI). (SERM – selective estrogen receptor modulator) 
Combinatio
n 
Drug1 Drug class Drug2 Drug class PCI 
DC01 Cabozantini
b 
VEGFR inhibitor Erlotinib EGFR inhibitor 0.60 
DC02 
Cabozantini
b 
VEGFR inhibitor Raloxifene SERM 0.50 
DC03 Olaparib PARP-1 inhibitor Tanespimycin HSP inhibitor 0.88 
DC04 Olaparib PARP-1 inhibitor Dinaciclib CDK inhibitor 1.0 
DC05 Olaparib PARP-1 inhibitor PD-0332991 CDK inhibitor 0.72 
DC06 Cabozantini
b 
VEGFR inhibitor PD-0332991 CDK inhibitor 0.34 
DC07 Paclitaxel Microtubule 
modulator 
Tanespimycin HSP inhibitor 0.38 
DC08 Paclitaxel 
Microtubule 
modulator 
Midostaurin 
VEGFR 
inhibitor 
0.44 
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DC09 
Cabozantini
b 
VEGFR inhibitor Trastuzumab HER2 inhibitor 0.57 
DC10 
Figitumuma
b 
IGF-1R inhibitor Raloxifene SERM 0.80 
 
 
 
 
 
 
Figure legends 
Figure 1. Pathway crosstalk inhibition. 
A. Crosstalk identified between pathways A and B, defined as shared protein 
interactions, or those occurring downstream of them, in the individual pathways. 
The flow of information within the crosstalk network, i.e., the network efficiency, 
is 0.29. B. Drug 1 inhibits signaling through pathway A but does not affect 
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crosstalk inhibition. In consequence, proliferation is not effectively inhibited. C. 
Drug 2 reduces signaling through the crosstalk network to 0.05, resulting in a 
pathway crosstalk inhibition of 0.83. D. Crosstalk signaling is completely 
prevented by using D1 and D2 in combination.  
Figure 2. In silico validation of the pathway crosstalk inhibition (PCI) index. 
A. Comparison of the PCI distributions for the populations of clinically relevant 
breast cancer drug combinations (i.e. currently in use or in clinical trials) and 
randomly combined breast cancer drugs (p-value = 8.96 x 10-6) as well as for 
combinations with and without confirmed clinical benefit (p-value = 0.03215). B. 
Evaluation of the PCI of 13 synergistic combinations with 55 non-synergistic (p-
value = 0.00341), 35 additive (p-value = 0.01667) and 20 antagonistic (p-value = 
0.00069) drug pairs identified among 14 targeted compounds within a 
liposarcoma cell line (16). P-value legend: * p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001. 
Figure 3. Pathway crosstalk inhibition between pairs of breast cancer 
therapeutics, both approved and experimental.  
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Drug combinations in use are indicated with a black dot. Combinations selected 
for experimental validation are marked with a red star (see also Table 1). Drugs 
are colored according to their therapeutic classes. Drugs not involved in any 
pathway crosstalk or its inhibition were removed for better illustration. Note that 
drugs belonging to the same class might still target different sets of proteins, 
and thus the crosstalk inhibition achieved when combined with other drugs 
might vary.  
Figure 4. Effect of different drug combinations on selected human cancer 
cell lines. 
A. Overview of the main molecular characteristics of the four breast cancer cell 
lines (in gray) and the osteosarcoma cell line (U2OS). B. Experimental DCI values 
derived for each combination and cell line at an inhibition level of 50%. A DCI50 
of zero depicts drug combinations in which none of the single agents yields an 
IC50 but the combination does. Blank cells indicate combinations for which no 
dose-response curves could be modeled (3 cases) or in which neither the single 
nor the dual perturbation reached the IC50 (5 cases). The histogram shows the 
distribution of DCI50 values for breast cancer cell lines only. 
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Figure 5. Pharmacodynamic interaction between raloxifene and 
cabozantinib.  
Isobologram showing the interaction behavior between raloxifene and 
cabozantinib. Blue and green symbols denote the IC50 of raloxifene and 
cabozantinib, respectively, while the red symbol represents the combination. 
The dotted line indicates additivity. Data points below this line display synergy, 
while points above imply antagonism. The dose reduction index (DRI) exhibits to 
which extent the concentration of a drug in combination can be reduced at a 
given inhibition level compared to the single concentrations. 
Figure 6. Effect of raloxifene, cabozantinib and combinatorial treatment on 
tumor growth in a MCF-7 xenograft model.  
A. Athymic nude mice, orthotopically injected with 1x106 MCF-7 cells, were 
treated for 15 days with cabozantinib (2 mg/kg), raloxifene (6 mg/kg), the 
combination of cabozantinib (1 mg/kg) and raloxifene (3 mg/kg), or vehicle. 
Single treatments were combined with the corresponding vehicle of the other 
drug. Tumor size was measured at the indicated times and was normalized 
according to the original size of each tumor at the start of the treatment. Nine 
mice with two tumors each were used per condition B. Representative TUNEL 
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staining of tumors collected at day 15. Significant increases in cell death levels 
were measured for cabozantinib (p-value = 0.0015) and the combination (p-
value = 0.00016) compared to vehicle. C. Average area of positive TUNEL-
stained cells quantified by ImageJ for each treatment. D. Representative H&E 
and Ki67 staining of the initial tumor, vehicle, cabozantinib and raloxifene alone, 
and the combination of both at day 15. Images shown are 20X. The percentage 
of positive Ki67-stained cells is indicated below each group. E. Visualization of 
the simplified crosstalk network between the estrogen and the VEGFR signaling 
pathway for DC02. Proteins analyzed by Western Blot (WB) are colored from 
yellow to blue. F. Western blot analysis of phospho-Akt, phospho-Src, Bcl-2 and 
Cyclin D1 to assess their activity with respect to pathway crosstalk inhibition. 
Tubulin was used as a loading control. 






